Last updated: September 24, 2026
HIVID, Roche’s brand for zalcitabine, was an early nucleoside reverse-transcriptase inhibitor approved by the FDA in 1992 for use with other antiretroviral agents. Its commercial position deteriorated as HIV treatment moved from dual-nucleoside regimens to combination therapy built around better-tolerated nucleoside analogues and protease inhibitors. Roche discontinued HIVID in 2006 after demand declined and treatment guidelines moved away from zalcitabine. The product has no meaningful current U.S. commercial market, no current branded revenue base, and no material modern generic-entry opportunity.
What was HIVID and how did zalcitabine work?
HIVID contained zalcitabine, also known as ddC, a cytidine analogue in the nucleoside reverse-transcriptase inhibitor, or NRTI, class. After intracellular phosphorylation, zalcitabine inhibited HIV reverse transcriptase by competing with natural nucleosides and terminating viral DNA synthesis.
The product was administered orally and was indicated only in combination with other antiretroviral drugs. HIVID was not positioned as monotherapy because HIV treatment required combination regimens to suppress viral replication and limit resistance.
| Attribute |
HIVID / zalcitabine |
| Brand |
HIVID |
| Active ingredient |
Zalcitabine, ddC |
| Drug class |
NRTI |
| Original sponsor |
Hoffmann-La Roche |
| U.S. FDA approval |
1992 |
| Dosage form |
Oral tablets |
| Historical use |
Combination treatment for HIV infection |
| Principal safety concerns |
Peripheral neuropathy, pancreatitis, oral and esophageal ulceration |
| U.S. commercial status |
Discontinued |
| Current market position |
No meaningful commercial market |
The FDA label identified peripheral neuropathy and pancreatitis as major risks. These toxicities limited the product’s utility, especially as alternatives with more favorable tolerability became available.[1]
When did HIVID lose exclusivity and when was it discontinued?
HIVID lost practical commercial exclusivity well before Roche withdrew it. Its commercial decline resulted from both competitive substitution and safety limitations rather than from a single modern patent-expiration event.
HIVID regulatory timeline
| Date |
Event |
| 1992 |
FDA approved HIVID for use with other antiretroviral agents.[2] |
| 1990s |
HIV treatment shifted toward multidrug regimens incorporating protease inhibitors and newer NRTIs. |
| Late 1990s to early 2000s |
Zalcitabine use declined as clinicians favored better-tolerated alternatives. |
| 2000s |
HIVID became a marginal product in treatment guidelines and prescribing. |
| 2006 |
Roche discontinued commercial availability in the United States. |
| Present |
HIVID is not an active branded growth product and is not a relevant component of current HIV treatment markets. |
The FDA’s discontinued-drug records distinguish commercial discontinuation from withdrawal for safety or effectiveness. HIVID’s withdrawal from commercial distribution reflected the product’s declining clinical and commercial relevance, not a newly identified regulatory finding that the drug was ineffective.[3]
What drove HIVID’s market decline?
HIVID faced a structural market decline caused by clinical substitution, adverse-event burden, and the changing economics of HIV treatment.
Clinical substitution
Zalcitabine competed with zidovudine, didanosine, stavudine, lamivudine, and later tenofovir-based therapies. Lamivudine became particularly important because it was generally easier to use and had a more favorable tolerability profile. Combination products also reduced the commercial appeal of a standalone zalcitabine tablet.
The introduction of highly active antiretroviral therapy in the mid-1990s altered the treatment market. Protease inhibitors and additional NRTIs enabled more effective multidrug regimens. HIVID was not a central component of the newer standard regimens.
Safety limitations
Peripheral neuropathy was a major limitation. Pancreatitis also constrained use and created monitoring concerns. The FDA label warned that neuropathy could be dose-limiting and that pancreatitis could become severe or fatal.[1]
The product’s risk profile affected both physician preference and payer positioning. A drug with significant toxicity and no clear efficacy advantage faced increasing pressure once alternatives became available.
Formulation and adherence disadvantages
HIVID was sold as a separate oral product rather than as part of a widely used fixed-dose combination. HIV treatment increasingly rewarded products that simplified dosing and reduced pill burden. Zalcitabine did not participate in the fixed-dose combination trend that later supported products such as Combivir, Trizivir, Atripla, and other combination regimens.
Resistance and treatment sequencing
NRTI resistance patterns also reduced the strategic value of zalcitabine. As patients received multiple antiretroviral agents over time, physicians increasingly selected drugs with stronger positions in guideline-based treatment algorithms and better resistance-management profiles.
What was HIVID’s financial trajectory?
Roche did not publicly report HIVID revenue as a standalone line item in its regular financial disclosures. The product’s sales were included within broader pharmaceutical reporting, making a precise product-level revenue curve unavailable from public company filings.
The economic trajectory can be divided into four phases:
| Phase |
Market condition |
Financial effect |
| Launch and early adoption, 1992-1995 |
HIV treatment had limited options and NRTIs were central to therapy. |
Initial commercial opportunity. |
| Combination-therapy expansion, 1996-1999 |
Protease inhibitors and newer NRTIs reshaped treatment. |
Rapid loss of strategic importance. |
| Mature decline, 2000-2005 |
Better-tolerated drugs and fixed-dose combinations displaced zalcitabine. |
Low and declining sales contribution. |
| Discontinuation, 2006 |
Roche exited commercial distribution. |
Revenue effectively ended in the United States. |
HIVID was never comparable in commercial scale to Roche’s later major products. Its revenue exposure was limited by the size of the early HIV market, competition from multiple NRTIs, and the rapid pace of therapeutic replacement.
The key financial conclusion is that HIVID was a declining legacy product rather than a product exposed to a discrete patent cliff. Its revenue erosion likely occurred over several years as prescribing moved to competing therapies. Roche’s decision to discontinue the product was consistent with low remaining demand and the cost of maintaining manufacturing, regulatory, distribution, and pharmacovigilance infrastructure for a shrinking product.
What patents protected HIVID and how strong was the patent estate?
The relevant intellectual-property position consisted primarily of historical composition, nucleoside-analogue, pharmaceutical-composition, and potentially manufacturing rights associated with zalcitabine and its use in HIV treatment. Those rights are expired or commercially irrelevant in the United States.
There is no current U.S. patent barrier protecting a viable HIVID franchise. Any original patent rights associated with zalcitabine would have expired decades ago under the pre-1995 patent-term framework or under the later 20-year-from-filing framework, depending on the specific family and jurisdiction.
Patent-estate assessment
| Patent factor |
HIVID assessment |
| Active U.S. composition-of-matter protection |
No commercially relevant protection |
| Active U.S. formulation protection |
No commercially relevant protection |
| Active method-of-use protection |
No commercially relevant protection |
| Patent-term extension exposure |
No current commercial significance |
| Patent litigation risk |
Negligible |
| Manufacturing know-how barrier |
Low for a technically capable generic manufacturer |
| Regulatory exclusivity |
Expired |
| Current franchise protection |
None of practical importance |
A historical patent search would need to separate patents covering zalcitabine itself from patents covering broader nucleoside analogues, synthesis intermediates, salt forms, formulations, and combination therapy. Those distinctions matter for archival patent analysis but do not change the current commercial conclusion.
What was the Orange Book status of HIVID?
HIVID was historically approved under an FDA new drug application, but it is not a current commercial Orange Book opportunity. The product’s U.S. approval and listing history are relevant to regulatory research, while its discontinued status eliminates the practical value of a present-day Paragraph IV strategy.
Paragraph IV challenges and generic entry
There is no active, economically meaningful Paragraph IV challenge to HIVID comparable to current disputes involving high-revenue small-molecule products. A generic company could theoretically pursue approval of zalcitabine under an abbreviated pathway if the product remained commercially attractive and regulatory requirements could be met. The market opportunity is too limited to support a meaningful launch thesis.
Potential barriers are commercial rather than patent-based:
- Very limited clinical demand.
- Outdated treatment positioning.
- Safety concerns associated with neuropathy and pancreatitis.
- Availability of better-supported antiretroviral options.
- Lack of inclusion in contemporary first-line HIV regimens.
- Limited payer and prescriber incentive to adopt a discontinued legacy NRTI.
What FDA regulatory issues affect HIVID?
The FDA-approved label required combination use and included prominent warnings for toxicity. HIVID’s regulatory profile is therefore central to its commercial decline.
The principal FDA-related factors were:
- The drug was not positioned as modern first-line monotherapy.
- Use required combination treatment.
- Peripheral neuropathy limited chronic use.
- Pancreatitis created serious safety-management obligations.
- Later treatment standards favored newer, better-tolerated agents.
- Commercial discontinuation ended the product’s active U.S. market presence.
The FDA’s records on discontinued drugs are important because they indicate whether a product was removed for safety or effectiveness reasons. HIVID’s commercial discontinuation does not create a current regulatory restriction on zalcitabine as a molecule, but it leaves the product without meaningful market support.[3]
How did HIVID compare with competing HIV drugs?
| Drug |
Class |
Historical competitive position |
Relative status versus HIVID |
| Zidovudine |
NRTI |
Foundational early HIV therapy |
Larger historical role |
| Didanosine |
NRTI |
Important early combination partner |
Competing legacy product |
| Stavudine |
NRTI |
Widely used in early combination therapy |
Stronger historical uptake, later toxicity concerns |
| Lamivudine |
NRTI |
Durable use in combination regimens |
Better tolerability and stronger commercial longevity |
| Tenofovir disoproxil fumarate |
NRTI |
Major later-generation backbone |
Superior modern treatment relevance |
| Emtricitabine |
NRTI |
Widely used in fixed-dose combinations |
Stronger adherence and combination-product position |
| Protease inhibitors |
Protease inhibitor class |
Reshaped HIV treatment after 1996 |
Reduced reliance on older NRTI-only strategies |
HIVID’s weakness was not simply that it had competitors. It was displaced by a treatment architecture that favored more effective combinations, improved tolerability, simpler dosing, and fixed-dose products.
Which companies challenged or replaced HIVID?
No current company is pursuing a material commercial challenge to HIVID. The competitive pressure came from manufacturers of alternative antiretrovirals rather than from a litigation-led generic event.
Historical competitors included:
- Glaxo Wellcome and later GlaxoSmithKline, through zidovudine and lamivudine products.
- Bristol-Myers Squibb, through didanosine and stavudine.
- Gilead Sciences, through tenofovir-based therapies.
- Merck, Abbott, Roche, and other companies active in protease inhibitors and combination treatment.
- Generic manufacturers supplying older antiretroviral ingredients after patent and regulatory barriers diminished.
The competitive landscape moved toward combination products and newer backbones. HIVID did not retain a differentiated clinical or commercial position.
Does HIVID face biosimilar risk?
No. HIVID is a small-molecule drug, not a biologic. Biosimilar regulation under the Biologics Price Competition and Innovation Act does not apply.
Any hypothetical follow-on product would be a conventional generic or an alternative small-molecule product, subject primarily to abbreviated new drug application requirements, bioequivalence, manufacturing controls, labeling, and commercial demand.
What licensing deals affected HIVID?
No material current licensing deal affects HIVID. Roche was the principal commercial sponsor, and the product’s commercial discontinuation ended the strategic importance of licensing rights associated with the brand.
Historical development and commercialization arrangements may exist in the broader intellectual-property record for nucleoside analogues, but they do not create a current licensing market for HIVID. No active partnership is relevant to revenue generation, market access, or exclusivity.
What patent litigation affected HIVID?
HIVID has no material current patent litigation. Its relevant patent rights are expired, and its commercial discontinuation removes the economic basis for a major infringement dispute.
Any historical litigation involving nucleoside analogues or HIV combination patents should be distinguished from litigation specifically concerning HIVID, zalcitabine, or Roche’s commercial product. Broader HIV patent disputes do not establish current protection for HIVID.
What generic launch scenarios exist for HIVID?
A commercial generic launch is unlikely despite the absence of meaningful patent protection.
| Scenario |
Probability assessment |
Commercial rationale |
| U.S. generic launch for broad HIV treatment |
Low |
Limited demand and obsolete treatment position |
| Hospital or government procurement niche |
Low |
Current guidelines favor other agents |
| Authorized legacy supply |
Very low |
No visible branded franchise to support it |
| Global low-resource-market use |
Limited |
Alternatives and procurement standards reduce opportunity |
| Reformulated or combination product |
Remote |
No established demand for zalcitabine-based combinations |
The absence of patent protection does not create an attractive generic opportunity. The principal risk to a potential entrant is demand destruction, not patent enforcement.
What is the geographic coverage and remaining commercial exposure?
HIVID’s active commercial exposure is effectively zero in the United States. Historical availability may have existed in other countries, but international sales would also have been constrained by the same clinical and competitive forces.
The product’s remaining value is primarily archival:
- Historical HIV-treatment research.
- Patent and regulatory-history analysis.
- Toxicology and pharmacovigilance review.
- Comparative analysis of early NRTIs.
- Academic study of antiretroviral market evolution.
There is no meaningful current revenue exposure for Roche, no active U.S. exclusivity value, and no practical biosimilar or generic threat to a current franchise.
Key Takeaways
- HIVID was Roche’s zalcitabine product and received FDA approval in 1992.
- The drug was an early NRTI used in combination HIV therapy.
- Peripheral neuropathy and pancreatitis weakened its clinical position.
- Newer NRTIs, protease inhibitors, and fixed-dose combinations displaced HIVID.
- Roche discontinued the product in 2006.
- Roche did not report HIVID revenue as a standalone financial category.
- The product’s decline was driven by therapeutic substitution and low demand, not a single patent cliff.
- No commercially meaningful active U.S. patent, Orange Book, Paragraph IV, litigation, licensing, or biosimilar issue remains.
- A generic launch is technically possible but commercially unattractive.
- HIVID has no meaningful current revenue or competitive-market exposure.
FAQs
Is HIVID still available in the United States?
No. Roche discontinued HIVID in the United States in 2006, and it is not a meaningful current treatment option.
What is the generic name for HIVID?
The generic name is zalcitabine, also known as ddC.
Why was HIVID discontinued?
The product lost clinical and commercial relevance because of toxicity concerns, including peripheral neuropathy and pancreatitis, and competition from newer antiretroviral regimens.
Was HIVID a biologic or a small-molecule drug?
HIVID was a small-molecule NRTI. It is not subject to biosimilar regulation.
Could a company still launch a generic version of zalcitabine?
A company could theoretically seek approval, but the limited demand, outdated treatment position, and safety profile make a commercial launch unlikely.
References
-
Hoffmann-La Roche Inc. (2001). HIVID (zalcitabine) tablets prescribing information. U.S. Food and Drug Administration.
-
U.S. Food and Drug Administration. (1992). HIVID approval history and labeling records. Drugs@FDA.
-
U.S. Food and Drug Administration. (2023). Discontinued drug product list. Center for Drug Evaluation and Research.
-
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
-
Roche Holding Ltd. (1992-2006). Annual reports and pharmaceutical business disclosures. Basel, Switzerland: Roche.
